

final_qualification_opinion_-_pd_imaging_biomarker



20 May 2016
EMA Qualification Opinion 16354/1/2015
Committee for Medicinal Products for Human Use (CHMP)

Qualification opinion on dopamine transporter imaging
as an enrichment biomarker for Parkinson's disease
clinical trials in patients with early Parkinsonian
symptoms

Draft agreed by Scientific Advice Working Party	20 October 2017
Adopted by CHMP for release for consultation	09 November 2017 ¹
Start of public consultation	24 January 2018 ²
End of consultation (deadline for comments)	07 March 2018 ³
Adoption by CHMP	28 April 2018

Keywords	Biomarker, Molecular neuroimaging, Parkinson's disease
-----------------	--

¹ List of relevant documents meeting

² List of documents on the EMA website

³ EMA website

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Information on the EMA website

EMA website

